CC
EIGR

Caxton Corporation’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Caxton Corporation’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,896
Closed -$880K – 19
2022
Q3 		$880K Hold
3,896
– – 1.65% 11
2022
Q2 		$736K Hold
3,896
– – 0.99% 11
2022
Q1 		$970K Hold
3,896
– – 1.21% 13
2021
Q4 		$607K Sell
3,896
-791
-17% -$153K 0.5% 38
2021
Q3 		$939K Buy
4,687
+66
+1% +$15.7K 0.76% 18
2021
Q2 		$1.18M Buy
4,621
+1,485
+47% +$371K 0.81% 15
2021
Q1 		$833K Buy
3,136
+501
+19% +$158K 0.54% 18
2020
Q4 		$972K Sell
2,635
-1,127
-30% -$323K 0.61% 16
2020
Q3 		$919K Buy
3,762
+1,029
+38% +$320K 0.87% 12
2020
Q2 		$787K Buy
2,733
+12
+0.4% +$3.54K 0.83% 11
2020
Q1 		$555K Buy
2,721
+651
+31% +$208K 0.61% 11
2019
Q4 		$925K Buy
2,070
+3
+0.1% +$1.06K 0.89% 11
2019
Q3 		$636K Buy
2,067
+4
+0.2% +$1.3K 0.72% 13
2019
Q2 		$656K Buy
2,063
+420
+26% +$145K 0.75% 12
2019
Q1 		$689K Buy
1,643
+186
+13% +$74.6K 0.64% 13
2018
Q4 		$444K Buy
1,457
+607
+71% +$196K 0.54% 15
2018
Q3 		$306K Buy
+850
New +$291K 0.28% 21

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Caxton Corporation's EIGR Position: Q4 2022 in Review

Caxton Corporation sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2022, closing a stake of 3,896 shares — an estimated $880K sold.

Caxton Corporation first reported a position in EIGR in Q3 2018 and held it in 17 quarters. The position peaked at $1.18M in Q2 2021. 81 funds tracked by Wall St. Rank hold EIGR as of Q4 2022.

  • Caxton Corporation reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
  • Caxton Corporation sold 3,896 Eiger BioPharmaceuticals, Inc. shares in Q4 2022, an estimated $880K.
  • Caxton Corporation first reported a position in Eiger BioPharmaceuticals, Inc. in Q3 2018 and held it in 17 quarters.
  • Caxton Corporation's Eiger BioPharmaceuticals, Inc. position peaked at $1.18M in Q2 2021.
  • 81 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2022.

Based on Caxton Corporation's 13F filing for Q4 2022, filed 14 Feb 2023.